Natco Pharma's Canadian Subsidiary Invests $8 Million in Xenotransplant Pioneer eGenesis

Natco Pharma Ltd's Canadian subsidiary has invested $8 million to acquire 40 million shares in eGenesis Inc., a leader in xenotransplantation. eGenesis is focused on developing human-compatible organs for transplant. The investment aims to support eGenesis's groundbreaking work in kidney, liver, and heart transplant programs.

Natco Pharma Ltd has made a significant investment in the field of xenotransplantation through its Canadian subsidiary, acquiring 40 million shares in eGenesis Inc. for $8 million.

eGenesis Inc., known for its pioneering work in developing human-compatible organs for transplant, employs a unique Genome Engineering and Production platform that addresses molecular incompatibilities and viral risks across species.

With this investment, eGenesis plans to advance its ongoing kidney, liver, and heart transplant programs, aiming to meet the global demand for organ transplants and reduce waitlist mortality. The collaboration has been praised by both companies' CEOs, signaling a promising future in organ transplant technology.

(With inputs from agencies.)